Skip to main content

Louis Drapeau, Philip Padou, Richard Begley, Per Petersen, Ismail Kola, Steven Kriegsman, Mark Ahn, Stephen Galliker, Sanford Hillsberg

Premium
Bio-Rad last week appointed Louis Drapeau to its audit committee. He will stand for election at a board meeting in April. Drapeau fills the space left open by the death late last year of Philip Padou.
 
Drapeau is currently CFO and senior vice president of finance at Nextar Therapeutics. He also served as CEO, CFO, and senior vice president at BioMarin Pharmaceutical, and was an executive in accounting and he serves on the board of directors at Inflazyme Pharmaceuticals.
 

 
PerkinElmer last week appointed Richard Begley vice president and general manager of its Analytical Sciences business.
 
In this position, Begley will “develop and lead the growth strategy” globally for the firm’s entire portfolio of analytical instrumentation, which includes chromatography, atomic and molecular spectroscopy, thermal analysis, and laboratory information management systems.
 
Begley joins PerkinElmer from Ensemble Discovery, where he was president and CEO. Before this he was CEO and president of 454 Life Sciences.
 

 
Per Petersen has been appointed to Invitrogen’s board of directors after retiring from his post at the chairman of R&D at Johnson & Johnson, the company said this week.
At J&J, Peterson was responsible for the Office of Science and Technology, the R&D Council, and the cell therapy research and activities. Prior to that, Peterson was chairman of the Department of Immunology at the Scripps Research Institute.
 

 
Ismail Kola has been named CSO and senior vice president of discovery research at the Schering-Plough Research Institute, the company said this week. Kola replaces Catherine Strader, who now is senior vice president of science and technology.
 
Kola will now be responsible for a 1,000-person team of researchers in the US and in Italy, and will be a member of the company’s operations management team.
 
Strader will be involved in external science and technology enterprises such as business development and licensing.
 

 
RXi Pharmaceuticals, a pure-play RNAi technology company and subsidiary of CytRx, has formed a five-member board of directors.
 
The board includes: Todd Woolf, president and CEO of RXi; Steven Kriegsman, who was president and CEO of CytRx; Mark Ahn, president and CEO of biopharmaceutical company Hana Biosciences; Stephen Galliker, executive vice president of finance and administration and CFO of Dyax; and Sanford Hillsberg, managing partner at the law firm Troy & Gould Professional.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.